bullish
Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
689 Views23 May 2019 09:44
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- ECM Weekly (1 Jun 2019) - Hansoh, China East Edu, GSX, CSSC (HK) Shipping, China Tobacco01 Jun 2019
- Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End30 May 2019
- Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal29 May 2019
- Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation23 May 2019
- Hansoh Pharma (翰森制药) IPO: Competitive Landscape of HS-10296, the 3rd Gen EGFR TKI for Lung Cancer21 May 2019
- Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)30 Apr 2019
x